Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 2255 |
| PDBID: | 6H1F |
| Chains: | A_B |
| Organism: | Lama glama, Homo sapiens |
| Method: | XRD |
| Resolution (Å): | 1.90 |
| Reference: | 10.1016/j.bbadis.2019.01.010 |
| Antibody | |
| Antibody: | Nb11 Nanobody |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Gelsolin |
| Antigen mutation: | Yes |
| Durg Target: | P06396 |
Sequence information
Antibody
Chain: A
Mutation: NULL
| >6H1F_A|Chain A|gelsolin nanobody, Nb11|Lama glama (9844) MQVQLQESGGGLVQAGGSLRLSCAASGRTFSSFVMGWFRQAPGKEREFVASISRSGSVTRYADSAKGRFTISKDNAKNTVSLQMDNLNPDDTAVYYCAADLHRPYGPGSQRTDDYDTWGQGTQVTVSSLVPRGSHHHHHH |
Antigen
Chain: B
Mutation: D40N
| >6H1F_B|Chain B|Gelsolin|Homo sapiens (9606) GSHHVVPNEVVVQRLFQVKGRRVVRATEVPVSWESFNNGNCFILDLGNNIHQWCGSNSNRYERLKATQVSKGIRDNERSGRARVHVSEEGTEPEAMLQVLGPKPALPAGTEDTAKEDAA |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| A: VAL2 ARG27 THR28 PHE29 SER30 SER31 PHE32 ARG53 ASP99 LEU100 HIS101 ARG102 PRO103 TYR104 ARG110 ASP112 ASP113 B: LEU193 ASN196 HIS198 ARG228 ARG230 HIS232 VAL233 SER234 THR238 GLU239 PRO240 GLU241 ALA242 LEU244 GLN245 GLY248 PRO249 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
